On August 3, 2023, the Canadian Agency for Drugs and Technologies in Health (CADTH) released its annual report. Highlights from 2022-2023 include:
- Development of procedures for review of nationally procured pharmaceuticals and delivery of implementation advice for certain COVID-19 treatments.
- Reports on evidence and resources for post-COVID condition (also known as long COVID).
- Creation of new reimbursement review pathways including the Non-Sponsored Single Drug Review and Streamlined Drug Class Review and a consultation on time-limited drug reimbursement recommendations.
- Creation of the Post-Market Drug Evaluation Program.
- Release of the 2023 Watch List: Top 10 Precision Medicine Technologies and Issues.
- Start of a learning period and development of draft guidance regarding the use of real-world evidence.
- Report on a potential pan-Canadian formulary.
Related Publications & Articles
-
PMPRB appoints Sharon Blady to Board and releases October 2024 NEWSletter
On October 17, 2024, the Minister of Health announced the appointment of Sharon Blady (the former Health Minister of Manitoba) to the Patented Medicine Prices Review Board (PMPRB).Read More -
Evolving pharmacy landscape signals more stringent regulatory scrutiny of “patient steering”
The pharmacy landscape has evolved considerably over the past year, shining a spotlight on pharmacy “patient steering”, the practice of directing patients to certain preferred pharmacies.Read More -
Government of Canada passes Pharmacare Act
On October 10, 2024, the Government of Canada announced that the Pharmacare Act received royal assent and came into force.Read More